Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC
Paul Chauvet
(1)
,
Annalisa Paviglianiti
(2)
,
Myriam Labopin
(2)
,
Hélène Labussiere
(3)
,
Nicolas Boissel
(4, 5)
,
Marie Robin
(5)
,
Natacha Maillard
(6)
,
Marie Ouachee-Chardin
(7)
,
Edouard Forcade
(8)
,
Xavier Poire
(9, 10)
,
Sylvain Chantepie
(11)
,
Anne Huynh
(12)
,
Claud E. Bulabois
(13)
,
Mathieu Leclerc
(14)
,
Sebastien Maury
(14)
,
Patrice Chevallier
(15)
,
Thomas Cluzeau
(16)
,
Jean-Baptiste Mear
(17)
,
Jerôme Cornillon
(18)
,
Karin Bilger
(19)
,
Célestine Simand
(19)
,
Yves Beguin
(20)
,
Marie-Thérèse Rubio
(21, 22)
,
Ibrahim Yakoub-Agha
(23)
,
Eolia Brissot
(2)
1
INFINITE -
Institute for Translational Research in Inflammation - U 1286
2 CRSA - Centre de Recherche Saint-Antoine
3 HCL - Hospices Civils de Lyon
4 IRSL - Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine ; ex- Institut Universitaire Hématologie-IUH)
5 AP-HP - Hopital Saint-Louis [AP-HP]
6 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
7 IHOPe - Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL]
8 CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux
9 Cliniques universitaires St Luc [Bruxelles]
10 UCL - Université Catholique de Louvain = Catholic University of Louvain
11 CHU Caen
12 Service Hématologie - IUCT-Oncopole [CHU Toulouse]
13 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
14 Hôpital Henri Mondor
15 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
16 CHU Nice - Centre Hospitalier Universitaire de Nice
17 Centre Hospitalier Universitaire [Rennes]
18 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
19 ICANS - Institut de Cancérologie de Strasbourg Europe
20 CHU-Liège - Centre Hospitalier Universitaire de Liège
21 Service d'Hématologie [CHRU Nancy]
22 IMoPA - Ingénierie Moléculaire et Physiopathologie Articulaire
23 LIRIC - Lille Inflammation Research International Center - U 995
2 CRSA - Centre de Recherche Saint-Antoine
3 HCL - Hospices Civils de Lyon
4 IRSL - Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine ; ex- Institut Universitaire Hématologie-IUH)
5 AP-HP - Hopital Saint-Louis [AP-HP]
6 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
7 IHOPe - Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL]
8 CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux
9 Cliniques universitaires St Luc [Bruxelles]
10 UCL - Université Catholique de Louvain = Catholic University of Louvain
11 CHU Caen
12 Service Hématologie - IUCT-Oncopole [CHU Toulouse]
13 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
14 Hôpital Henri Mondor
15 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
16 CHU Nice - Centre Hospitalier Universitaire de Nice
17 Centre Hospitalier Universitaire [Rennes]
18 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
19 ICANS - Institut de Cancérologie de Strasbourg Europe
20 CHU-Liège - Centre Hospitalier Universitaire de Liège
21 Service d'Hématologie [CHRU Nancy]
22 IMoPA - Ingénierie Moléculaire et Physiopathologie Articulaire
23 LIRIC - Lille Inflammation Research International Center - U 995
Marie-Thérèse Rubio
- Fonction : Auteur
- PersonId : 19145
- IdHAL : marie-therese-rubio
- ORCID : 0000-0003-3732-5442
- IdRef : 149394489
Eolia Brissot
- Fonction : Auteur
- PersonId : 1098504
- ORCID : 0000-0003-4471-418X
Résumé
Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (allo-HCT) still represents a major concern with poor outcomes. The aim of this study is to compare the efficacy and safety of blinatumomab and donor lymphocyte infusion (DLI) versus blinatumomab alone in this setting. This is a multicenter retrospective study from centers of SFGM-TC. All transplanted patients who received blinatumomab salvage therapy were included. Patients who received DLI from 1 month before to 100 days after the starting of blinatumomab were included in the blina-DLI group. Seventy-two patients were included. Medium follow-up was 38 months. Fifty received blinatumomab alone and 22 the association blinatumomab-DLI. Two-year overall survival (OS) was 31% in the blinatumomab group and 43% in the blinatumomab-DLI group (p = 0.31). Studying DLI as a time dependent variable, PFS did not significantly differ between the 2 groups (HR:0.7, 95% CI: 0.4–1.5). In multivariate analysis, DLI was not a prognostic factor for OS, progression-free survival and progression/relapse incidence. Adverse events and graft-versus-disease rates were comparable in the 2 groups. In conclusion, adding DLI between 1 month before and 100 days after start of blinatumomab is safe and does not seem to improve outcomes in B-ALL patients who relapsed after allo-HCT.